Oct 14, 2025: Driving breakthroughs with structure-guided drug design

The first challenge in drug discovery is selecting a biological target and validating it as a ‘druggable’ binding site. The key to this is identifying several potent compounds that can be used in more advanced validating assays. To achieve this go/no-go point, good chemical starting points need to be found and then compounds are optimised for binding.

In this webinar hosted by DDW, Curia shares its findings that protein X-ray crystallography is essential to accelerate the design process by providing a level of structural detail unmatched by computational methods.

What you will learn:

• Why accelerating the design of low nanomolar compounds is essential in target validation
• Structure-driven SAR process requires excellent structural biology, medicinal and computational integration
• The value of executing a structure-based strategy to fast-track drug delivery and invention

Register for webinar here